Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity

Curr Opin Pharmacol. 2017 Dec:37:10-15. doi: 10.1016/j.coph.2017.07.010. Epub 2017 Aug 10.

Abstract

Gut hormones have long been understood to regulate food intake and metabolism. Bariatric surgery significantly elevates circulating gut hormone levels and is proven to affect acute remission of type 2 diabetes before any weight loss is observed. Subsequent weight loss is accrued over weeks to months but is sustained into the long term. Hence, there exists great enthusiasm to recapitulate these changes in gut hormones in the form of novel combination drugs for type 2 diabetes and obesity.

Publication types

  • Review

MeSH terms

  • Animals
  • Cholecystokinin / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Gastric Inhibitory Polypeptide / metabolism
  • Gastrointestinal Tract / metabolism*
  • Glucagon-Like Peptide 1 / agonists
  • Glucagon-Like Peptide 1 / metabolism
  • Humans
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Oxyntomodulin / pharmacology
  • Peptide YY / metabolism

Substances

  • Oxyntomodulin
  • Peptide YY
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Cholecystokinin